Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib
Hematological Oncology2019Vol. 37(4), pp. 418–423
Citations Over Time
Francesca Palandri, Giuseppe A. Palumbo, Elisabetta Abruzzese, Alessandra Iurlo, Nicola Polverelli, Elena Maria Elli, Massimiliano Bonifacio, Micaela Bergamaschi, Bruno Martino, Mario Tiribelli, Giulia Benevolo, Alessia Tieghi, Nicola Sgherza, Alessandro Isidori, Gianni Binotto, Monica Crugnola, Florian H. Heidel, Francesco Cavazzini, Costanza Bosi, Giuseppe Auteri, Daniele Cattaneo, Robin Foà, Roberto M. Lemoli, Antonio Cuneo, Mauro Krampera, Daniela Bartoletti, Michèle Cavo, Nicola Vianelli, Massimo Breccia, Roberto Latagliata
Abstract
The 2016 WHO criteria identified early primary myelofibrosis (PMF) as an individual entity with milder clinical features and better outcome compared with overt PMF. Here, we compared early and overt PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response, and toxicity to treatment. We observed that early-PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of hematological toxicities. No differences in overall and leukemia-free survival were detected between the two cohorts. The application of 2016 WHO criteria is crucial to identify those PMF patients who deserve a stricter monitoring during treatment.
Related Papers
- → JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis(2012)1,766 cited
- → A Comprehensive Review of Pacritinib in Myelofibrosis(2015)34 cited
- → Erythematous skin lesions with necrotic centers on lower extremities due to the use of ruxolitinib for primary myelofibrosis(2018)5 cited
- → Comparing Eras in Myelofibrosis: Changing Patterns of Treatment Before and After FDA-Approval of Ruxolitinib(2016)
- → Myelofibrosis Management After Ruxolitinib Failure(2019)